An Online Survey on the Relationship Between Positive Coping and Post-Traumatic Stress Symptoms (PTSS) of Medical Students in China During the COVID-19 Pandemic: The Mediating Role of Social Support.

BACKGROUND The COVID-19 pandemic has caused varying degrees of psychological stress among medical students. This research explored the post-traumatic stress symptoms (PTSS) of medical students in China and their relationship with positive coping and social support. MATERIAL AND METHODS In the form of cross-sectional online survey, 2280 medical students locked down at home were selected by random cluster method to investigate social support, coping style, and PTSS using the Social Support Rating Scale (SSRS), Simplified Coping Style Questionnaire (SCSQ), and Post-traumatic Stress Disorder (PTSD) Checklist-Civilian Version (PCL-C), respectively. RESULTS This research found that the PTSS detection rate in medical students was 10.42% during the COVID-19 pandemic. The PTSS scores of females were significantly higher than that of the males. However, the PTSS detection rate in females (9.71%) was not significantly different from that in males (11.24%). Compared with those of the non-PTSS group, the total score and its all-factor score of social support, the total score of coping style and the positive coping score of the PTSS group were much lower, while the negative coping score of the PTSS group was much higher (P<0.01). Positive coping was positively correlated with social support, while positive coping and social support were negatively correlated with PTSS. The total effect of positive coping on PTSS was -0.310 (P<0.001), the direct effect was -0.128 (P<0.01), and the indirect effect was -0.182 (P<0.001). Social support played a mediating role between positive coping and PTSS, with the mediating effect accounting for 58.81% of the total effect. CONCLUSIONS Social support plays a mediating role between positive coping and post-traumatic stress symptoms. Objective support and positive coping are the 2 main protective factors of PTSS.

Clinical characteristics of patients with SARS-CoV-2 Delta variant infection in Gansu Province

Objective: To summarize the clinical characteristics of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant infection by comparing with patients with wild strain infection in Gansu Province. Methods: Totally 141 patients diagnosed with Delta variant infection(variant group)and 88 patients with COVID- 19 (wild strain group) in Gansu Province were selected, and their clinical data were retrospectively collected and compared. Results The proportion of patients with hypertension and vaccination was higher in the variant group than in the wild strain group (P < 0.05). Most of the two groups were mild and common types, and there were no statistically significant differences in the other general data (all P > 0.05). The percentages of fever, fatigue, muscle soreness, chest tightness and shortness of breath in the variant group were lower than those in the wild group, and the proportion of sore throat was higher than that in the wild group (all P < 0.05). The proportions of white blood cells (WBC) < 4.0 x 109/L, platelets (PLT) < 100x109/L, glutamyl transpeptidase (GGT) > 50.0 U/L, lactate dehydrogenase (LDH) > 240.0 U/L, blood urea nitrogen (BUN) > 7.1 mmol/L, and international normalized ratio (INR) >1.13 were all lower in the variant group than in the wild strain group (all P < 0.05);the percentage of aspartate aminotransferase (AST) > 40 U/L was higher than that of the wild strain group (P < 0.05). No significant differences were found in the alanine aminotransferase (ALT), blood creatinine (Cr), creatine kinase (CK), creatine kinase isoenzyme (CK-MB), activated partial thromboplastin time (APTT), prothrombin time (PT), calcitoninogen (PCT), or C-reactive protein (CRP) between these two groups (all P > 0.05). The proportions of abnormal chest CT, bilateral lesions, and three or more lobar lesions were significantly lower in the variant group than in the wild strain group (all P < 0.05). The proportions of treatments with interferon, ribavirin, lopinavir/ritonavir, antibiotics, glucocorticoids, immunoglobulins, hemopexin, Abidor tablets, and oxygen were lower in the variant group than in the wild strain group (all P < 0.05). The proportions of treatments with prone ventilation, anticoagulation, neutralizing antibodies, thymofacine, and hepatoprotective therapy were higher in the variant group than in the wild strain group (all P < 0.05). Thirty-five cases (53.0%) of lymphocytes in the wild strain group did not return to normal levels at discharge, and the differences in the time to recovery of lymphocytes, time to absorption of lung lesions, and time to nucle ic acid conversion between the two groups were not statistically significant (all P > 0.05). The recovery time of oxygen saturation (SaO2) in the variant group was shorter than that in the wild strain group, and the time of nucleic acid conversion and hospitalization was longer than that in the wild strain group (all P < 0.05). There were two deaths (2.3%) in the wild strain group and 0 death in the variant group, with no statistically significant difference between the two groups (P > 0.05). Conclusions: Compared with patients with wild strain infection, patients with Delta variant infection are mainly of light and common type with high vaccination coverage, smaller lung lesion involvement, shorter SaO2 recovery time, but longer nucleic acid regression time and hospitalization time, and have a good prognosis after oxygen therapy, traditional Chinese medicine, immune boosting, etc. The prognosis is good after conventional treatment.

Trends in managing COVID-19 from an emerging infectious disease to a common respiratory infectious disease: What are the subsequent impacts on and new challenges for healthcare systems?

Targeting the 9 countries with the highest cumulative number of newly confirmed cases in the past year, we analyzed the case fatality ratio (CFR) among newly confirmed cases and the vaccination rate (two or more doses of vaccine per 100 people) in the United States of America (USA), India, France, Germany, Brazil, the Republic of Korea, Japan, Italy, and the United Kingdom (UK) for the period of 2020-2022. Data reveal a decrease in the CFR among newly confirmed cases since the beginning of 2022, when transmission of the Omicron variant predominates, and an increase in vaccination rates. The Republic of Korea had the lowest CFR among newly confirmed cases (0.093%) in 2022 and the highest vaccination rate (86.27%). Japan had the second highest vaccination rate (83.12%) and a decrease in the CFR among newly confirmed cases of 1.478% in 2020, 1.000% in 2021, and 0.148% in 2022; while the average estimated fatality ratio for seasonal influenza from 2015-2020 was 0.020%. Currently, most countries are now easing COVID-19-related restrictions and are exploring a shift in management of COVID-19 from an emerging infectious disease to a common respiratory infectious disease that can be treated as the equivalent of seasonal or regional influenza. However, compared to influenza, infection with the Omicron variant still has a higher fatality ratio, is more transmissible, and the size of future outbreaks cannot be accurately predicted due to the uncertainty of viral mutation. More importantly, as countries shift their response strategies to COVID-19, there is an urgent need at this time to clarify what the subsequent impacts on healthcare systems and new challenges will be, including the clinical response, the dissemination of scientific information, vaccination campaigns, the creation of future surveillance and response systems, the cost of treatments and vaccinations, and the flexible use of big data in healthcare systems.

An average of nearly 200,000 new infections per day over a six-week period: What is the impact of such a severe COVID-19 pandemic on the healthcare system in Japan?

During a six-week period from July 20 to August 31, 2022, Japan experienced its highest level of COVID-19 infection ever, with an average of nearly 200,000 new infections per day nationwide. Cases requiring inpatient care peaked at 1,993,062. Twenty-seven prefectures (out of 47 prefectures) had an average hospital bed occupancy of 50% or higher, and bed occupancy in Kanagawa in particular reached 98% in mid-August. In Tokyo, bed occupancy by patients with severe COVID-19 reached 57% and peaked at 64% in mid-August. Although the number of new infections per day has decreased since September, hospital bed occupancy, the number of severe cases, and deaths remain high nationwide. Efforts including vaccination campaigns, domestic surveillance, and routine infection control measures based on the varied knowledge that the Japanese public already has should be thoroughly implemented to reduce the number of the infected in order to avoid an increase the number of serious cases and deaths.

COVID-19 in Japan: An update on national policy, research, clinical practice, and vaccination campaign.

As countries worldwide take steps such as vaccination campaigns to combat the COVID-19 pandemic, academia is actively promoting the timely sharing of scientific information across borders. As an international academic journal, Global Health & Medicine (GHM) has quickly accepted COVID-19-related papers and published results of series of studies since the beginning of 2020. In particular, the "First Special Issue on COVID-19" (April 2020) and the "Second Special Issue on COVID-19" (April 2021) included a wide range of articles presenting frontline data on the COVID-19 response in Japan, China, the United States, Italy, the United Kingdom, West Africa, and other various countries and areas worldwide. This "Third Special Issue on COVID-19" (April 2022) features the practical experiences of front-line clinicians, researchers, and other healthcare professionals from Japan and it presents updated data on i) national policy, ii) research, iii) clinical practice, and iv) the vaccination campaign. Our hope is that the rapid publication and sharing of information will help, in any way possible way, in the global fight against COVID-19.

Distribution and Drug Resistance of Bacterial Pathogens Associated with Lower Respiratory Tract Infection in Children and the Effect of COVID-19 on the Distribution of Pathogens.

By studying the distribution and drug resistance of bacterial pathogens associated with lower respiratory tract infection (LRTI) in children in Chengdu and the effect of the COVID-19 on the distribution of pathogens and by analyzing the epidemic trend and drug resistance changes of the main pathogens of LRTI, this research is supposed to provide a useful basis for the prevention of LRTI in children and the rational use of drugs in clinical practice. Hospitalized children clinically diagnosed with LRTI in Chengdu Women and Children's Central Hospital from 2011 to 2020 were selected as the study subjects. The pathogens of LRTI in children and the distribution of pathogens in different ages, genders, seasons, years, and departments and before and after the pandemic situation of COVID-19 were counted. The drug resistance distribution of the top six pathogens with the highest infection rate in the past three years and the trend of drug resistance in the past decade were analyzed. A total of 26,469 pathogens were isolated. Among them, 6240 strains (23.6%) were Gram-positive bacteria, 20152 strains (76.1%) were Gram-negative bacteria, and 73 strains (0.3%) were fungi. Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, and Staphylococcus aureus were highly isolated in the group of infants aged 0-1 (P < 0.01), Moraxella catarrhalis and Streptococcus pneumoniae were highly isolated in children aged 1-6 (P < 0.01), and Haemophilus influenzae was highly isolated in children over 1 (P < 0.01). The isolation rates of Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Staphylococcus aureus, and Candida albicans in the lower respiratory tract of 0-1 year-old male infants were higher than those of female infants (p < 0.05). Haemophilus influenzae was highly isolated in spring and summer, and Moraxella catarrhalis was highly isolated in autumn and winter, while the infection of Streptococcus pneumoniae was mainly concentrated in winter. This difference was statistically significant (P < 0.01). Affected by the COVID-19 pandemic, the isolation rates of Haemophilus influenzae and Streptococcus pneumoniae were significantly lower than those before the pandemic, and the isolation rate of Moraxella catarrhalis was significantly higher. The difference was statistically significant (P < 0.01). The proportion of isolated negative bacteria in NICU and PICU was higher than that in positive bacteria, and the infection rates of Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, and Acinetobacter baumannii were higher than those in other departments. The differences were statistically significant (P < 0.01). The results of drug sensitivity test showed that the drug resistance of Haemophilus influenzae and Moraxella catarrhalis was mainly concentrated in Ampicillin, First- and Second-generation cephalosporins, and Cotrimoxazole, with stable sensitivity to Third-generation cephalosporins, while the drug resistance of Streptococcus pneumoniae was concentrated in Macrolides, Sulfonamides, and Tetracyclines, with stable sensitivity to Penicillin. Staphylococcus aureus is highly resistant to penicillins and macrolides and susceptible to vancomycin. Enterobacteriaceae resistance is concentrated in cephalosporins, with a low rate of carbapenem resistance. From 2018 to 2020, 1557 strains of Staphylococcus aureus were isolated, of which 416 strains were MRSA, accounting for 27% of the isolates; 1064 strains of Escherichia coli were isolated, of which 423 strains were ESBL and 23 strains were CRE, accounting for 40% and 2% of the isolates, respectively; and 1400 strains of Klebsiella pneumoniae were isolated, of which 385 strains were ESBL and 402 strains were CRE, accounting for 28% and 29% of the isolates, respectively. Since 2011, the resistance of Escherichia coli and Klebsiella pneumoniae to Third-generation cephalosporins has increased, peaking in 2017, and has decreased after 2018, years after which carbapenem resistance has increased significantly, corresponding to an increase in the detection rate of Carbapenem-resistant Enterobacteriaceae CRE. Findings from this study revealed that there are significant differences in community-associated infectious pathogens before and after the COVID-19 pandemic, and there are significant age differences, seasonal epidemic trends, and high departmental correlation of pathogens related to lower respiratory tract disease infection in children. There was a significant gender difference in the isolation rate of pathogens associated with LRTI in infants under one year. Vaccination, implementation of isolation measures and social distance, strengthening of personal protective measures, aseptic operation of invasive medical treatment, hand hygiene, and environmental disinfection are beneficial to reducing community-associated pathogen infection, opportunistic pathogen infection, and an increase in resistant bacteria. The strengthening of bacterial culture of lower respiratory tract samples by pediatricians is conducive to the diagnosis of respiratory tract infections caused by different pathogens, contributing to the selection of effective drugs for treatment according to drug susceptibility results, which is important for the rational use of antibiotics and curbing bacterial resistance.

Increasing demand for point-of-care testing and the potential to incorporate the Internet of medical things in an integrated health management system.

As the number of people with COVID-19 increases daily around the world, point-of-care testing (POCT) is gaining attention as a tool that can provide immediate test results and greatly help to deter infection and determine what to do next. POCT has several drawbacks such as a low sensitivity and specificity, but according to studies POCT has increased sensitivity on par with that of polymerase chain reaction testing. The advantage of POCT is that the results can be obtained quickly, regardless of the location. To further enhance its benefits, POCT is being developed and researched in conjunction with the Internet of medical things (IoMT), which allows POCT results to be collected, recorded, and managed over a network. IoMT will be beneficial not only for the use of POCT simply as a testing tool but also for its integration into diagnostic and health management systems. IoMT will enable people to regularly receive their test results in their daily lives and to provide personalized diagnosis and treatment of individual conditions, which will be beneficial in terms of disease prevention and maintenance of health.

The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines.

Over the past 2 years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease 2019 (COVID-19) and rapidly spread worldwide. In the process of evolution, new mutations of SARS-CoV-2 began to appear to be more adaptable to the diverse changes of various cellular environments and hosts. Generally, the emerging SARS-CoV-2 variants are characterized by high infectivity, augmented virulence, and fast transmissibility, posing a serious threat to the prevention and control of the global epidemic. At present, there is a paucity of effective measurements to cure COVID-19. It is extremely crucial to develop vaccines against SARS-CoV-2 and emerging variants to enhance individual immunity, but it is not yet known whether they are approved by the authority. Therefore, we systematically reviewed the main characteristics of the emerging various variants of SARS-CoV-2, including their distribution, mutations, transmissibility, severity, and susceptibility to immune responses, especially the Delta variant and the new emerging Omicron variant. Furthermore, we overviewed the suitable crowd, the efficacy, and adverse events (AEs) of current vaccines.

The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China.

OBJECTIVE: In order to fight against coronavirus disease 2019 (COVID-19) better and to share our experience as a reference for clinical laboratory departments. METHODS: This was a retrospective study conducted in the clinical laboratory department of Chengdu Women's and Children's Central Hospital in Chengdu, China, from April 2020 to January 2021. The number of nucleic acid and antibody testing specimens of suspected COVID-19 cases was analyzed. The key points of suspected-case sample processing and detection in the clinical laboratory department were summarized. The laboratory was directly involved in the sample processing and testing of suspected cases, the release of reports, and the transfer of specimens to the fever clinic. RESULTS: The number of COVID-19 nucleic acid test specimens in our laboratory ranged from 102 to 2170 per day, and the number of antibody test specimens ranged from 24 to 391 per day. There were four main considerations in the treatment and detection of suspected-case specimens in the clinical laboratory: biosafety management in clinical laboratory departments, measures to ensure the health of the staff, the eight time points for processing suspected-case samples (turn-around time), and key points for the detection of suspected case specimens. CONCLUSION: The laboratory developed a protective process for COVID-19 antibody and nucleic acid detection during the pandemic. At present, the detection of COVID-19 antibodies and nucleic acids in the clinical laboratory department is orderly, and there have been no cases of laboratory infection.

Infectious disease activity during the COVID-19 epidemic in Japan: Lessons learned from prevention and control measures.

In Japan, the Law Concerning the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (the "Infectious Diseases Control Law") classifies infectious diseases as category I-V infectious diseases, pandemic influenza, and designated infectious diseases based on their infectivity, severity, and impact on public health. COVID-19 was designated as a designated infectious disease as of February 1, 2020 and then classified under pandemic influenza as of February 13, 2021. According to national reports from sentinel surveillance, some infectious diseases transmitted by droplets, contact, or orally declined during the COVID-19 epidemic in Japan. As of week 22 (June 6, 2021), there were 704 cumulative cases of seasonal influenza, 8,144 cumulative cases of chickenpox, 356 cumulative cases of mycoplasma pneumonia, and 45 cumulative cases of rotavirus gastroenteritis; these numbers were significantly lower than those last year, with 563,487 cumulative cases of seasonal influenza, 31,785 cumulative cases of chickenpox, 3,518 cumulative cases of mycoplasma pneumonia, and 250 cumulative cases of rotavirus gastroenteritis. Similarly, many infectious diseases transmitted by droplets or contact declined in other countries and areas during the COVID-19 pandemic. One can reasonably assume that various measures adopted to control the transmission of COVID-19 have played a role in reducing the spread of other infectious diseases, and especially those transmitted by droplets or contact. Extensive and thorough implementation of personal protective measures and behavioral changes may serve as a valuable reference when identifying ways to reduce the spread of infectious diseases transmitted by droplets or contact in the future.

Behavioral changes adopted to constrain COVID-19 in Japan: What are the implications for seasonal influenza prevention and control?

Respiratory disease deaths associated with seasonal influenza are estimated to be 290,000 to 650,000 per year globally. In Japan, seasonal influenza affects more than 10 million people per year, and especially children, the elderly, and patients with underlying medical conditions, and seasonal influenza can cause severe illness. As SARS-CoV-2 continues to spread, the combined risk of concurrent influenza epidemics and the COVID-19 pandemic are a concern. When the status of influenza virus infections during the 2020-2021 flu season was compared to the 2011 to 2020 flu seasons, data indicated the absence of seasonal influenza outbreaks in Japan during the COVID-19 pandemic. The number of flu patients was roughly estimated to be 14,000 nationwide from September 2020 to March 2021, which marks the first sharp decrease since national influenza surveillance started in 1987 in conjunction with National Epidemiological Surveillance of Infectious Diseases (NESID). Moreover, approximately 500 sentinel sites (designated medical facilities) nationwide reported only 112 patients with severe influenza who required hospitalization. Since prevention and control measures amidst the COVID-19 pandemic have become the "new normal", one can reasonably assume that the absence of a seasonal influenza outbreak is related to prevention and control measures implemented in response to the COVID-19 pandemic. Basic infection prevention measures were thoroughly implemented, such as wearing masks, handwashing, and avoiding confined spaces, crowded places, and close-contact settings. More importantly, the behavioral changes adopted to constrain COVID-19 during three declared states of emergency reduced population density and contact with people, including closing schools, asking restaurants to reduce their business hours, teleworking, curbing the flow of people during vacation week, etc. These behavioral changes will serve as a valuable reference to reduce the spread of seasonal influenza in the future.

Overview of the characteristics of and responses to the three waves of COVID-19 in Japan during 2020-2021.

The first case of COVID-19 in Japan was reported on 16 January 2020. The total number of the infected has reached 313,844 and the number of deaths has reached 4,379 as of 16 January 2021. This article reviews the characteristics of and responses to the three waves of COVID-19 in Japan during 2020-2021 in order to provide a reference for the next step in epidemic prevention and control. The Japanese Government declared a state of emergency on 7 April 2020, which suppressed the increase in the number of the infected by curtailing economic activity. The first wave peaked at 701 new cases a day and it decreased to 21 new cases on May 25 when the state of emergency was lifted. However, the number of the infected increased again due to the resumption of economic activity, with a peak of 1,762 new cases a day during the second wave. Although the situation was worse than that during the first wave, the government succeeded in limiting the increase without declaring a state of emergency again, and that may be attributed to a decrease in crowd activities and an increase in the number of inspections. During the third wave, the number of the infected continued to exceed the peak during previous waves for two months. Major factors for this rise include the government's implementation of further policies to encourage certain activities, relaxed immigration restrictions, and people not reducing their level of activity. An even more serious problem is the bed usage for patients with COVID-19; bed usage exceeds 50% not only in major cities but also in various areas. On 7 January 2021, 5,953 new cases were reported a day; this greatly exceeded the previous peak, and the state of emergency was declared again. Although Japan has been preparing its medical system since the first wave, maintaining that system has imposed a large economic burden on medical facilities, hence stronger measures and additional support are urgently needed to combat COVID-19 in the coming few months.

Shifting workstyle to teleworking as a new normal in face of COVID-19: analysis with the model introducing intercity movement and behavioral pattern.

BACKGROUND: Instead of the complete lockdown, since the outbreak of coronavirus disease 2019 (COVID-19), Japan has been trying to control the infection by self-restraint request policy. It seems that the number of infected people has subsided, however, the increasing human activities again in the resumption of economy may lead to the second wave of infections. Here, we analyzed the major factors behind the success control of the first outbreak in Japan and the potential risk of the second wave. METHODS: Employing a localized stochastic transition model, we analyze the real data and the results of simulation in Tokyo from March 1 to July 31. In the model, population is divided into three compartments: susceptible, infected, and removed; and area into three zones: crowded, mid and uncrowded. Different zones have different infection probabilities characterized by the number of people gathered there. The flow of the infection simulation in one day consists of three steps: (I) intercity movement of population, (II) isolating infected people, and (III) zone shifting following group behavioral patterns. RESULTS: The major cause for the success of controlling the first outbreak in Tokyo is demonstrated through our simulation to be the early request of self-restraint as well as the early detection of infected people. Meanwhile, the observation that the increasing human activities again in the resumption of economy will lead to the second wave of infections is also found in the simulation with an extended period. Based on the analysis of intercity movement and behavioral pattern on Tokyo where normally about 2.9 million people come from the surrounding cities to the central area by using the public railway system every day, results showed that turning the workstyle of 55% of working people ranging in age from 20 to 64 years old into teleworking (remote work) may control the spread of infection without significant economic damage. Meanwhile, to keep about 75% of the normal activity level and to advocate the shift to telework are indispensable because a sudden resumption of activity from the lockdown sate can rapidly spread infection. CONCLUSIONS: As a new normal in face of COVID-19 for Tokyo and other cities that with a high population density, shifting the workstyle of 55% of working people to teleworking and to reduce 25% time staying in the high infection risk area could be an effective measure to control the spread of infection while maintaining a certain level of economic activity.

Cytokine storm induced by SARS-CoV-2.

Coronavirus disease 2019 (COVID-19), caused by the virus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread widely throughout the world. Despite the strict global outbreak management and quarantine measures that have been implemented, the incidence of COVID-19 continues to rise, resulting in more than 290,000 deaths and representing an extremely serious threat to human life and health. The clinical symptoms of the affected patients are heterogeneous, ranging from mild upper respiratory symptoms to severe pneumonitis and even acute respiratory distress syndrome (ARDS) or death. Systemic immune over activation due to SARS-CoV-2 infection causes the cytokine storm, which is especially noteworthy in severely ill patients with COVID-19. Pieces of evidence from current studies have shown that the cytokine storm may be an important factor in disease progression, even leading to multiple organ failure and death. This review provides an overview of the knowledge on the COVID-19 epidemiological profile, the molecular mechanisms of the SARS-CoV-2-induced cytokine storm and immune responses, the pathophysiological changes that occur during infection, the main antiviral compounds used in treatment strategies and the potential drugs for targeting cytokines, this information is presented to provide valuable guidance for further studies and for a therapeutic reduction of this excessive immune response.

An international comparison analysis of reserve and supply system for emergency medical supplies between China, the United States, Australia, and Canada.

Coronavirus disease 19 (COVID-19) has become a pandemic around the world. With the explosive growth of confirmed cases, emergency medical supplies are facing global shortage, which restricts the treatment of seriously ill patients and protection of medical staff. Taking China, the United States, Australia, and Canada as examples, this study compares and analyzes the reserve and supply systems of emergency medical supplies and problems exposed in response to the COVID-19 epidemic. Some common problems were found, such as insufficient types and quantities of emergency medical supplies in reserve, insufficient emergency production capacity, and imperfect command mechanism for emergency supplies deployment and transportation. A sound reserve system of emergency medical supplies is the basis and guarantee for dealing with public health emergencies such as major outbreaks. Based on the comparison of systems and practical experience, countries around the world should further improve the reserve and supply system of emergency medical supplies, and improve the coordination and cooperation mechanism for emergency supplies for international public health emergencies, so as to cope with increasingly severe public health emergencies in the context of globalization.

Scientific solidarity in the face of the COVID-19 pandemic: researchers, publishers, and medical associations.

In the face of COVID-19, the scientific community has rapidly come together to address this outbreak in an open and collaborative manner to support the global response to this outbreak by rapidly sharing and highlighting research data and relevant findings. COVID-19 research is being published at a furious pace. Over 6,000 articles have been published as of 20 April 2020, and at least 15 online resource centers/websites for COVID-19 have been created by publishers to enable fast and free access to the latest research, evidence, and data available. Moreover, many evidence-based guidelines for COVID-19 have been issued based on academic articles and summaries of the experiences of frontline medical personnel. Various academic medical associations are also actively sharing information and providing technical support. As an example, 93 guides/proposals/responses to COVID-19 have been issued so far by 50 medical associations in Japan. However, few publications and national situation reports have provided information on the number of infected healthcare workers (HCWs). More publications and national situation reports are urgently needed to provide scientific information to devise specific infection prevention and control measures in order to protect HCWs from infection.

Analysis of COVID-19 infection spread in Japan based on stochastic transition model.

To assess the effectiveness of response strategies of avoiding large gatherings or crowded areas and to predict the spread of COVID-19 infections in Japan, we developed a stochastic transmission model by extending the Susceptible-Infected-Removed (SIR) epidemiological model with an additional modeling of the individual action on whether to stay away from the crowded areas. The population were divided into three compartments: Susceptible, Infected, Removed. Susceptible transitions to Infected every hour with a probability determined by the ratio of Infected and the congestion of area. The total area consists of three zones crowded zone, mid zone and uncrowded zone, with different infection probabilities characterized by the number of people gathered there. The time for each people to spend in the crowded zone is curtailed by 0, 2, 4, 6, 7, and 8 hours, and the time spent in mid zone is extended accordingly. This simulation showed that the number of Infected and Removed will increase rapidly if there is no reduction of the time spent in crowded zone. On the other hand, the stagnant growth of Infected can be observed when the time spent in the crowded zone is reduced to 4 hours, and the growth number of Infected will decrease and the spread of the infection will subside gradually if the time spent in the crowded zone is further cut to 2 hours. In conclusions The infection spread in Japan will be gradually contained by reducing the time spent in the crowded zone to less than 4 hours.

COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern.

Rapidly sharing scientific information is an effective way to reduce public panic about COVID-19, and doing so is the key to providing real-time guidance to epidemiologists working to contain the outbreak, clinicians managing patients, and modelers helping to understand future developments and the possible effectiveness of various interventions. This issue has rapidly reviewed and published articles describing COVID-19, including the drug treatment options for SARS-CoV-2, its clinical characteristics, and therapies involving a combination of Chinese and Western medicine, the efficacy of chloroquine phosphate in the treatment of COVID-19 associated pneumonia according to clinical studies, and reflections on the system of reserve medical supplies for public health emergencies. As an academic journal, we will continue to quickly and transparently share data with frontline healthcare workers who need to know the epidemiological and clinical features of COVID-19.